Log In
Print this Print this

Lumigan 0.01%

  Manage Alerts
Collapse Summary General Information
Company Allergan plc
Description0.01% bimatoprost
Molecular Target
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationOcular hypertension
Indication DetailsTreat intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today